| NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer and viral infectious diseases. NK cells are the body's first line of defense due to their innate ability to seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or activation by other support molecules required to train and activate adaptive immune cells such as T-Cells. Co. holds the exclusive right to commercialize activated NK cells, a commercially viable natural killer cell line, and a range of genetically modified derivatives capable of killing cancer and virally infected cells. We show 25 historical shares outstanding datapoints in our coverage of NK's shares outstanding history.|
Understanding the changing numbers of NK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NK by allowing them to research NK shares outstanding history
as well as any other stock in our coverage universe.